China’s Big And Small Next-Gen Sequencing Players Ride The Precision Medicine Wave
This article was originally published in Clinica
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.
Three months after publishing its draft guideline on biosimilars, China's Food and Drug Administration (CFDA) has just released the final official version, although it is still described as a pilot scheme. The new guideline may look similar to the draft on the surface, but a closer comparison reveals many differences.